摘要
目的探讨重组人脑利钠肽(rhBNP)联合左西孟旦治疗对顽固性心力衰竭(RHF)患者心功能及N末端B型利钠肽原(NT-proBNP)水平的影响。方法选取80例RHF患者随机分为两组,各40例。对照组采用左西孟旦治疗,观察组则采用rhBNP联合左西孟旦治疗。两组均连续治疗1周。比较两组患者的治疗效果、心功能、NT-proBNP水平及不良反应发生率。结果观察组治疗总有效率为95.00%,明显高于对照组的77.50%(P<0.05)。治疗后,观察组左室射血分数(LVEF)水平高于对照组,左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)及NT-proBNP水平低于对照组(P<0.05)。治疗期间观察组的不良反应发生率为12.50%,与对照组的7.50%比较无统计学差异(P>0.05)。结论rhBNP联合左西孟旦治疗RHF患者的效果显著,可明显改善患者的心功能,降低NT-proBNP水平,降低不良反应发生风险。
Objective To expore the influence of recombinant human brain natriuretic peptide(rhBNP)combined with levosimendan on cardiac function and N-terminal pro-B-type natriuretic peptide(NT-proBNP)level in patients with refractory heart failure(RHF).Methods 80 RHF patients were selected and randomly divided into two groups,with 40 cases in each group.The control group was treated with levosimendan,and the observation group was treated with rhBNP combined with levosimendan.Both groups were treated continuously for 1 week.The treatment effect,cardiac function,NT-proBNP level and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 95.00%,significantly higher than 77.50%in the control group(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)level of the observation group was higher than that of the control group,and the left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)and NT-proBNP levels were lower than those of the control group(P<0.05).No statistical difference was found in the incidence of adverse reactions(12.50%vs.7.50%)between the two groups(P>0.05).Conclusions rhBNP combined with levosimendan has significant effect in the treatment of RHF,and can significantly improve the cardiac function,reduce the NT-proBNP level and the risk of adverse reactions.
作者
王付川
王金花
VANG Fuchuan;WANG Jinhua(2^(nd)Department of Cardiology,Nanyang Second People's Hospital,Nanyang 473000,China)
出处
《临床医学工程》
2023年第11期1525-1526,共2页
Clinical Medicine & Engineering
